Pituitary Growth Hormone Release Research Articles

THU043 Single-cell Transcriptomics Show Sex-specific Responses To A High Fat Diet, Under Thermoneutral Conditions, Pointing To Reduced Pituitary Plasticity

Abstract Disclosure: T.K. Miles: None. A.N. Lagasse: None. A.K. Odle: None. S.S. Lira: None. M.M. Syed: None. N. Akhter: None. M.C. MacNicol: None. A.M. MacNicol: None. G.V. Childs: None. Hyperinsulinemia caused by a high fat diet (HFD) directly suppressed pituitary growth hormone (Gh) and growth hormone releasing hormone receptor (Ghrhr) mRNAs (Luque and Kineman, 2006). To study the broader impact of a HFD, we exposed 3 groups of FVB.129P mice to 60% HFD for 10 or 15 wks at thermoneutrality (TN) (30 C), or 15 wks at room temperature (RT). Pituitary transcript expression was analyzed with single-cell RNA-seq. HFD-fed mice gained >20 g by 12 wks, showing increased serum leptin (1.8-2X), insulin (2-8X) and IL-6 (4-6X), decreased glucose clearance after a glucose challenge and decreased respiratory quotient indicating fat burning. Activity was unaffected by HFD. Rank plot analyses showed reduced amplitude GH pulses in HFD females fed at RT (15 wks), but not in mice fed at TN. Serum levels of other pituitary hormones were unaffected in HFD females. In HFD males, only serum TSH was elevated significantly (1.8X, 15 wks, TN). Analysis of the scRNA-seq data detected separate clusters representing each cell type. Two multihormonal cell clusters evident in control females mostly disappeared following HFD (15 wks, RT). At the threshold cutoff of avg Log2FC±0.5 with adj p<0.05, female somatotrope clusters showed reduced Pomc, Cga, and ribosomal proteins. Female lactotrope clusters exhibited decreased Gh mRNA (avg Log2FC -1.8 or -2.5) and galanin at 10 wks (TN). At 15 wks (TN), lactotrope clusters showed significant changes in 46 transcripts including reductions in Prl, 29 ribosomal proteins, galanin, and 3 transcriptional regulators. Notably, this cluster showed an increase in synaptotagmin-4 (Syt4), which is also elevated in oxytocin neurons following a HFD. Stem cell clusters in females were strongly impacted by HFD after 15 weeks (TN) with 94 reduced transcripts of which 48 were involved in cytoplasmic translation and ribosome biogenesis and >20 were involved with signaling and cell differentiation. In males, whereas changes in most clusters fell below the threshold cutoffs, stem cell clusters had 13 reduced transcripts after 10 or 15 weeks, most of which involved immune system processes including defense responses and antigen processing and presentation. The GH deficiency in mice fed under thermoneutral conditions was not as severe as that reported by Luque and Kineman, perhaps due to differences in strain, sex, and/or the environmental temperature. The reduced expression of multihormonal clusters, Gh by lactotropes and corticotropes, and Cga and Pomc by somatotropes suggests that HFD may reduce plasticity and activity of progenitor cells in the pituitary. The changes in lactotropes and somatotropes also indicate that HFD may compromise ribosome function and cytoplasmic translation. The reduced transcriptome in stem cells in both males and females suggests HFD interference with cell differentiation and pituitary plasticity as well as dysfunctional immune defense responses. Presentation: Thursday, June 15, 2023

Growth hormone secretagogue peptide A233 upregulates Mx expression in teleost fish in vitro and in vivo.

Aquaculture constitutes an alternative source for food production and contributes to a reduction in the indiscriminate catching of aquatic organisms in their natural environment. However, high mortality during the larval state remains a challenge in this sector, mainly because of factors such as diet and diseases caused by pathogens. Therefore, growth and health management is a key strategy for sustainable aquaculture. Synthetic growth hormone secretagogues (GHSs) are a family of ligands that can stimulate pituitary growth hormone release as well as the function of ghrelin, contributing to the immune responses in a variety of vertebrates, including fish. The A233 decapeptide is a GHS with a demonstrated impact on growth, immune system function, and antioxidant defense in tilapia fish, but no antiviral activity has been described for this peptide. Here, using an in vitro model (TRG-2 cells) and two in vivo models (sea bream [Sparus aurata]) and zebrafish [Danio rerio]), we demonstrate for the first time the potential antiviral effect of A233 in teleost fish.

Effects of Ghrelin on intestinal cell proliferation, the expression of protein absorption and metabolism factors in juvenile grass carp (Ctenopharyngodon idella)

Ghrelin can stimulate pituitary growth hormone (GH) release, and has a key role in the regulation of food intake and adiposity in vertebrates. At present, no relevant studies have reported the effects of Ghrelin on intestinal cell proliferation, protein absorption and metabolism. In this paper, firstly we established the intestinal epithelial cell lines of juvenile grass carp (Ctenopharyngodon idella) that can be passed stably and identified by the intestinal specific expression proteins E-cadherin and ZO-1. And we used this cell line as a model to investigate the effects of Ghrelin, Ala-Gln, Ala-Gln+Ghrelin on the proliferation of juvenile grass carp intestinal cells. We found that the use of Ghrelin, Ala-Gln and Ala-Gln+Ghrelin could promote the proliferation of intestinal cells of juvenile grass carp, but Ala-Gln+Ghrelin had the strongest promoting effect. Further, we investigated the effects of Ghrelin on the expression of cdx2, PepT1 and mTOR which are related to intestinal cell proliferation, protein absorption and metabolism of grass carp in vitro and in vivo experiments. And we studied the effects of different protein sources on the expression of Ghrelin, PepT1 and mTOR in grass carp at individual level. The results suggested that Ghrelin can promote grass carp intestinal cell proliferation, and affect the expression of genes which are related to intestinal peptide absorption and metabolism in juvenile grass carp.

Ghrelin Gene Deletion Alters Pulsatile Growth Hormone Secretion in Adult Female Mice.

Using preproghrelin-deficient mice (Ghrl-/-), we previously observed that preproghrelin modulates pulsatile growth hormone (GH) secretion in post-pubertal male mice. However, the role of ghrelin and its derived peptides in the regulation of growth parameters or feeding in females is unknown. We measured pulsatile GH secretion, growth, metabolic parameters and feeding behavior in adult Ghrl-/- and Ghrl+/+ male and female mice. We also assessed GH release from pituitary explants and hypothalamic growth hormone-releasing hormone (GHRH) expression and immunoreactivity. Body weight and body fat mass, linear growth, spontaneous food intake and food intake following a 48-h fast, GH pituitary contents and GH release from pituitary explants ex vivo, fasting glucose and glucose tolerance were not different among adult Ghrl-/- and Ghrl+/+ male or female mice. In vivo, pulsatile GH secretion was decreased, while approximate entropy, that quantified orderliness of secretion, was increased in adult Ghrl-/- females only, defining more irregular GH pattern. The number of neurons immunoreactive for GHRH visualized in the hypothalamic arcuate nucleus was increased in adult Ghrl-/- females, as compared to Ghrl+/+ females, whereas the expression of GHRH was not different amongst groups. Thus, these results point to sex-specific effects of preproghrelin gene deletion on pulsatile GH secretion, but not feeding, growth or metabolic parameters, in adult mice.

The Selective NMDA Receptor GluN2B Subunit Antagonist CP-101,606 with Antidepressant Properties Modulates Cytochrome P450 Expression in the Liver.

Recent research indicates that selective NMDA receptor GluN2B subunit antagonists may become useful for the treatment of major depressive disorders. We aimed to examine in parallel the effect of the selective NMDA receptor GluN2B subunit antagonist CP-101,606 on the pituitary/serum hormone levels and on the regulation of cytochrome P450 in rat liver. CP-101,606 (20 mg/kg ip. for 5 days) decreased the activity of CYP1A, CYP2A, CYP2B, CYP2C11 and CYP3A, but not that of CYP2C6. The alterations in enzymatic activity were accompanied by changes in the CYP protein and mRNA levels. In parallel, a decrease in the pituitary growth hormone-releasing hormone, and in serum growth hormone and corticosterone (but not T3 and T4) concentration was observed. After a 3-week administration period of CP-101,606 less changes were found. A decrease in the CYP3A enzyme activity and protein level was still maintained, though no change in the mRNA level was found. A slight decrease in the serum concentration of corticosterone was also maintained, while GH level returned to the control value. The obtained results imply engagement of the glutamatergic system in the neuroendocrine regulation of cytochrome P450 and potential involvement of drugs acting on NMDA receptors in metabolic drug–drug interactions.

Acute intravenous acyl ghrelin infusion induces thirst but does not affect sodium excretion: two randomized, double-blind, placebo-controlled crossover studies in hypopituitary patients.

Acyl ghrelin, which is the endogenous ligand for the growth hormone secretagogue receptor, potently stimulates pituitary growth hormone release, and to some degree adrenocorticotropic hormone and prolactin. Ghrelin is also orexigenic and has recently been shown to stimulate renal sodium absorption in rodent models. Increased thirst sensation has been observed as a side effect of acyl ghrelin administration in some human studies. The objective of this clinical trial was to investigate the direct effects of acyl ghrelin on thirst sensation and sodium excretion in hypopituitary patients. Hypopituitary patients on stable replacement with hydrocortisone and growth hormone were investigated in two double-blind and placebo-controlled crossover studies. The patients received a 5-h intravenous infusion of acyl ghrelin (5 pmol/kg/min in the first study and 1 pmol/kg/min in the second study). Thirst sensation was measured on a Visual Analog Scale (VAS). In the second study plasma osmolality, vasopressin, copeptin, water intake, diuresis and urinary excretion of sodium and creatinine were measured. In the initial study, acyl ghrelin (5 pmol/kg/min) increased thirst sensation (time × treatment analysis of variance for the effect of acyl ghrelin infusion P = 0.003). In the second study acyl ghrelin (1 pmol/kg/min) also increased thirst (P = 0.04) but did not affect urinary excretion of either sodium or water. We demonstrate that acyl ghrelin infusion increases thirst sensation, without affecting sodium excretion or diuresis in human subjects.

Serotonin Receptors of 5-HT2 Type in the Hypothalamic Arcuate Nuclei Positively Regulate Liver Cytochrome P450 via Stimulation of the Growth Hormone-Releasing Hormone/Growth Hormone Hormonal Pathway.

Our recent study carried out after local injection of the serotonergic neurotoxin 5,7-dihydroxytryptamine into the arcuate nucleus (ARC) of the hypothalamus suggested a positive influence of the serotonergic innervation of the ARC on growth hormone (GH) secretion and GH-dependent expression of cytochrome P450. The aim of our present study was to determine the effect of the activation of the serotonin (5-HT)-type receptors, 5-HT1 or 5-HT2, in the ARC on the expression and activity of cytochrome P450 in the liver of male rats. The serotonergic agonist 5-carboxyamidotryptamine [(5-CT), a 5-HT1-type receptor agonist] or 2,5-dimethoxy-4-iodoamphetamine [(DOI), a 5-HT2-type receptor agonist] was injected into the ARC for 5 days. The activity and expression of cytochrome P450 isoenzymes and the levels of serum and pituitary hormones were estimated. DOI significantly increased the activity and expression (both mRNA and protein levels) of CYP2C11, CYP3A1/23, and CYP3A2, which positively correlated with an increase in the pituitary growth hormone-releasing hormone (GHRH) and serum GH level. The injection of 5-CT into the ARC did not affect the activity of liver P450 enzymes or hormone levels. The obtained results indicate that 5-HT2, but not the 5-HT1-type receptors in the ARC, are engaged in the positive neuroendocrine regulation of cytochrome P450, possibly by the stimulation of hypothalamic GHRH release and pituitary GH secretion, and an increase in the serum GH concentration. Further studies are going to identify which of the 5-HT2 receptor subtypes (5-HT2A, 5-HT2B, or 5-HT2C) is responsible for the observed neuroendocrine regulation of cytochrome P450.

The nonapeptide isotocin in goldfish: Evidence for serotonergic regulation and functional roles in the control of food intake and pituitary hormone release

Nonapeptides are a highly conserved family of peptides synthesized in the neuroendocrine brain and acting on central and peripheral receptors to regulate physiological functions in vertebrates. While the evolution of the two gene families of oxytocin-like and vasopressin-like nonapeptides and their receptors, as well as the neuroanatomy of their independent neuronal circuits have been well-characterized across vertebrate species, comparative studies on the physiological roles across vertebrates are lagging behind. In the current study, we focused on the comparative neuroendocrine functions and regulation of isotocin, the teleost homologue of mammalian oxytocin. Specifically, we address the hypothesis that isotocin exerts opposing effects on food intake and reproduction, which are well-established effects of its homologue oxytocin in mammalian species. Using goldfish, a well-characterized model of neuroendocrine regulation of both food intake and reproduction, we here showed that isotocin acts as an anorexigenic factor while exerting stimulatory effects on pituitary luteinizing hormone and growth hormone release. Given the dual inhibitory and stimulatory roles of serotonin on food intake and pituitary release of reproductive hormone in goldfish, we also investigated the potential crosstalk between both systems using immunohistochemistry and pharmacological approaches. Results provide neuroanatomical and pharmacological evidence for serotonergic regulation of magnocellular isotocinergic neurons in the preoptic area and pituitary. Together, these findings firstly provide the basis to investigate neuroendocrine cross-talk between serotonergic and nonapeptidergic systems in the regulation of both food intake and reproduction in goldfish, and secondly point to a conserved function of oxytocin-like peptides in the differential neuroendocrine control of both physiological processes in vertebrates.

The effect of short-term hypothyroidism on growth hormone secretory responses to growth hormone-releasing hormone (1-29) and insulin-induced hypoglycemia

Introduction: Hypothyroidism is frequently associated with growth failure. In long-standing hypothyroidism the growth hormone (GH) secretory responses to growth hormone-releasing hormone (GRH) and insulin-induced hypoglycemia are decreased. Methods: To investigate whether hypothyroidism of short duration affects pituitary GH release, we measured the serum GH response to synthetic GRH (1-29), 1g/kg body weight, given IV to six athyreotic patients during thyroxine (T4) treatment and one month after stopping T4 (short-term hypothyroid state). This served as a direct measure of pituitary somatotroph function .We also assessed the serum GH response to insulin-induced hypoglycemia in three patients as an indirect assessment of hypothalamic function. Results: We found that basal GH levels remained the same both during (euthyroid state) and after stopping T4 therapy (hypothyroid state). Peak serum GH response to GRH was significantly greater in patients while they were hypothyroid than during T4 therapy when they were euthyroid (p

670 Growth hormone-induced signaling as a novel, intrafollicular neuroendocrine control of human hair growth

Growth hormone (GH) and activation of its receptor (GHR) promote cell growth, proliferation, differentiation and stem cell activation either directly or via the induction of IGF-1. While some clinical case reports suggest that human hair follicles (HFs) may be GH-responsive, it is unknown whether GH exerts any functions in human HF biology. To explore this we charted the expression of GH, GHR and GHRH (growth hormone releasing hormone), the hypothalamic neurohormone that stimulates pituitary GH expression and release, in human scalp HFs. So far, we have detected GH, GHR and GHRH protein expression in the ORS of human anagen VI HFs as well as in the sebaceous gland epithelium. qRT-PCR analysis revealed that human scalp HFs also transcribe GHR mRNA, supporting that human HFs are an extrapituitary source of GH production. qRT-PCR analysis showed that GHR transcription decreases during HF regression (catagen HFs). Interestingly, the level of GHR transcription was inversely correlated with that of the GH-inhibiting hormone, somatostatin (SST), whose expression increased in catagen HFs. Next, organ-cultured human scalp HFs were stimulated with recombinant hGH (rhGH, 50-100 ng/ml) or recombinant GH-binding protein (rGHBP), which can exert both GH-antagonistic and agonistic effects. hGH and GHBP both promoted hair shaft elongation and tended to inhibit catagen development ex vivo. qRT-PCR analysis showed that hGH (100 ng/ml) and GHBP (100 ng/ml) induced an increase in HF mRNA levels of JAK2, the downstream target after GHR activation, and of SST. While we are still investigating how GHR silencing in human HFs ex vivo impacts on standard hair biology read-out parameters, our pilot study already suggests that GHR-mediated signaling by intrafollicularly generated GH is as a major novel neuroendocrine regulator of human hair growth.

Sex biased expression of ghrelin and GHSR associated with sexual size dimorphism in yellow catfish

Sexual size dimorphism has been observed in many cultivable fish species including yellow catfish, in which male fish grow much faster than female fish. Ghrelin is a potent stimulator of pituitary growth hormone (GH) release and known to potentially promote food intake and body weight gain. In order to investigate the molecular mechanism of sexual size dimorphism in yellow catfish (Pelteobagrus fulvidraco), ghrelin and its functional receptor, growth hormone secretagogue receptor (GHSR) cDNAs were cloned. Real-time PCR indicated that both ghrelin and GHSR were more highly expressed in hypothalamus and gut of male fish than female. During normal larval development, expression of ghrelin and GHSR genes was significantly higher in males than in females. 17a-Methyltestosterone (MT) treatment enhanced the expression of ghrelin in female larval fish and GHSR in both sexes, whereas the expression of ghrelin in male larval fish increased in the beginning, then decreased as the treatment time prolonged. Furthermore, the expression of ghrelin and GHSR in male juvenile was significantly increased compared with female juvenile, in short and long term fasting periods, suggesting that male fish may have a better appetite than female during fasting. Our results demonstrate that sex difference in the expression of ghrelin and GHSR may be involved in sexual size dimorphism by regulating feeding and GH/IGF signaling in yellow catfish.

Effect of Deletion of Ghrelin-O-Acyltransferase on the Pulsatile Release of Growth Hormone in Mice.

Ghrelin, a gut hormone originating from the post-translational cleavage of preproghrelin, is the endogenous ligand of growth hormone secretagogue receptor 1a (GHS-R1a). Within the growth hormone (GH) axis, the biological activity of ghrelin requires octanoylation by ghrelin-O-acyltransferase (GOAT), conferring selective binding to the GHS-R1a receptor via acylated ghrelin. Complete loss of preproghrelin-derived signalling (through deletion of the Ghrl gene) contributes to a decline in peak GH release; however, the selective contribution of endogenous acyl-ghrelin to pulsatile GH release remains to be established. We assessed the pulsatile release of GH in ad lib. fed male germline goat(-/-) mice, extending measures to include mRNA for key hypothalamic regulators of GH release, and peripheral factors that are modulated relative to GH release. The amount of GH released was reduced in young goat(-/-) mice compared to age-matched wild-type mice, whereas pulse frequency and irregularity increased. Altered GH release did not coincide with alterations in hypothalamic Ghrh, Srif, Npy or Ghsr mRNA expression, or pituitary GH content, suggesting that loss of Goat does not compromise canonical mechanisms that contribute to pituitary GH production and release. Although loss of Goat resulted in an irregular pattern of GH release (characterised by an increase in the number of GH pulses observed during extended secretory events), this did not contribute to a change in the expression of sexually dimorphic GH-dependent liver genes. Of interest, circulating levels of insulin-like growth factor (IGF)-1 were elevated in goat(-/-) mice. This rise in circulating levels of IGF-1 was correlated with an increase in GH pulse frequency, suggesting that sustained or increased IGF-1 release in goat(-/-) mice may occur in response to altered GH release patterning. Our observations demonstrate that germline loss of Goat alters GH release and patterning. Although the biological relevance of altered GH secretory patterning remains unclear, we propose that this may contribute to sustained IGF-1 release and growth in goat(-/-) mice.

Ghrelin administration suppresses inflammation-associated colorectal carcinogenesis in mice.

Ghrelin is a 28-amino-acid peptide that stimulates the release of pituitary growth hormone. Because of its orexigenic effects, ghrelin is being developed as a therapeutic option for postoperative support and treatment of anorexia-cachexia syndrome of cancer patients. However, ghrelin has a multiplicity of physiological functions, and it also affects cell proliferation. Therefore, the effects of ghrelin administration on carcinogenesis and cancer progression in patients susceptible to cancer should be clarified. In this study, we examined the effects of ghrelin on cancer promotion in vivo using murine intestinal carcinogenesis models. Intestinal tumorigenesis was examined to determine the effects of either exogenous ghrelin administration or ghrelin deficiency following deletion of the Ghrl gene. Two murine intestinal tumorigenesis models were used. The first was the azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced inflammation-associated colon carcinogenesis model and the second was the ApcMin/+ genetic cancer susceptibility model. In AOM/DSS-treated mice, administration of ghrelin significantly suppressed tumor formation in the colon. In contrast, ghrelin administration did not affect the number of intestinal tumors formed in ApcMin/+ mice. The absence of endogenous ghrelin did not affect the incidence of intestinal tumors in either AOM/DSS-treated mice or ApcMin/+ mice, though tumor size tended to be larger in Ghrl−/− colons in the AOM/DSS model. No tumor-promoting effect was observed by ghrelin administration in either tumorigenesis model. In summary, this study provides in vivo experimental evidence for the usefulness of ghrelin administration in the chemoprevention of inflammation-associated colorectal carcinogenesis and may suggest its safety in patients under colitis-associated cancer susceptibility conditions.

Gene expression profiling reveals a possible role for somatostatin in the innate immune response of the liver.

Somatostatin is a neuropeptide hormone that inhibits pituitary growth hormone (GH) release. Using microarray analysis of gene expression in the livers of wildtype control and somatostatin knockout mice, we have previously identified a panel of genes whose GH-dependent and sexually dimorphic expression patterns are significantly altered by the absence of somatostatin (1). Here, we provide methodological and analytical details of that study, the raw data of which is deposited in the Gene Expression Omnibus as data set GSE56520. In addition, we performed further gene ontology analysis of the data and found that the differential expression of a second subset of genes in the livers of somatostatin-knockout mice versus wildtype controls is likely independent of GH signaling and involved in the innate immune response.

The somatotropic axis during the physiological estrus cycle in dairy heifers—Effect on hepatic expression of GHR and SOCS2

Pituitary growth hormone (GH) release and hepatic insulin-like growth factor-I (IGF-I) production increase after an injection of 17β-estradiol (E2) in ovariectomized dairy cattle. However, whether endogenous sexual steroid hormones also influence the hepatic GH receptor (GHR) signaling pathway during a physiological estrus cycle remains unclear. The aim of this study was to analyze the hepatic GHR signaling pathway during the luteal phase and after a period of increased E2 concentrations (after ovulation) as well as in 7 heifers before ovulation. Ovarian ultrasounds were performed daily during repeated physiological cycles (n=56) of 30 Holstein Friesian heifers to determine ovulation [before ovulation (n=7, bOv) and after ovulation 24–60h after the appearance of estrus signs (n=49, aOv)] and luteal phase (CLP; d 12±1 after ovulation). Blood samples and liver biopsies were obtained, and blood concentrations of E2, P4, insulin-like growth factor (IGF)-I, IGF-II, and GH were measured. In the liver biopsies, we determined mRNA expression of the estrogen receptor α (ERα), GHR, Janus kinase 2 (JAK2), signal transducer and activator of transcription 5B (STAT5B), suppressor of cytokine signaling (SOCS)2 and 3, IGF-I, and IGF-II by quantitative reverse transcription-PCR. The concentration of E2 was higher bOv than aOv and CLP, as expected. The concentrations of IGF-I and GH were higher bOv and aOv compared with CLP. In contrast, concentrations of IGF-II were lower aOv compared with bOv and CLP. The mRNA expression of GHR was higher in liver biopsies obtained bOv compared with aOv and CLP. Notably, the expression of SOCS2 was higher bOv than aOv and in the CLP. Increased hepatic expression of SOCS2 during estrus was detectable when IGF-I concentrations were high; this result might indicate that SOCS2 expression attenuates the GHR signal transduction pathway during the phase of increased pituitary GH release. In conclusion, hepatic GHR and SOCS2 mRNA expression appeared to be promptly and sensitively regulated by increased E2 levels before ovulation of dairy heifers.

Suppression of Insulin Secretion by Ghrelin and The Deterioration of Glucose Tolerance in Healthy Children

Background: Ghrelin, identified as an endogenous ligand for the growth hormone secretagogue receptor, functions as a somatotrophic and orexigenic signal from the stomach. The secretion of ghrelin increases under conditions of negative energy balance, such as starvation, cachexia, and anorexia nervosa, whereas its expression decreases under conditions of positive energy-balance such as feeding, hyperglycemia, and obesity. In addition to having a powerful effect on the secretion of growth hormone, ghrelin stimulates food intake and transduces signals to hypothalamic regulatory nuclei that control energy homeostasis. Thus, it is interesting to note that the stomach may play an important role in not only digestion but also as a pituitary growth hormone release and central feeding regulation.
 Objective: The goal of this study was to test the hypothesis that circulating ghrelin suppresses insulin secretion in healthy children.
 Subjects and methods: Enzyne-Linked immunosorbent assay method was used to assay Ghrelin and Insulin. By taking blood sample from 40 obese children, 11 overweight children and 29 normal weight healthy children their age (5-11) years.
 Results: the mean concentration of Ghrelin was significantly lower in obese and overweight children than in controls ( P < 0.000 ) . The mean concentration of Insulin was significantly higher in obese and overweight children than in controls ( P < 0.007 ). Negative correlations was obtained between Ghrelin and BMI, also negative correlation between Ghrelin and Insulin was obtained. 
 Conclusions: This study showed that ghrelin reduces insulin secretion and glucose disappearance in healthy children. This findings raise the possibility that endogenous ghrelin has a role in physiologic insulin secretion, and that its antagonist may improve β-cell function.

Does the dawn phenomenon have clinical relevance in normal pregnancy?

The dawn phenomenon is a transient rise in blood glucose between 4 and 6 am that is attributed to the pulsatile release of pituitary growth hormone (GH). In pregnancy, GH is suppressed by placental GH. Hence, we hypothesize that there is no evidence for the dawn phenomenon in late pregnancy in healthy women. Twenty glucose-tolerant women with singleton gestations between 28 weeks and 36 weeks 6 days' gestation were recruited. The women were admitted overnight to the Clinical Research Unit and had continuous glucose monitoring. Insulin and GH were measured at 2-hour intervals from 8 pm to 8 am. GH was grouped into times 1A (8-10 pm), 2A (12-2 am), and 3A (4-8 am) for changes over time. Further analysis was performed with time 1B (8 pm to 2 am) and 2B (4-8 am). Insulin was measured between 4 and 8 am. Plasma glucose decreased over time (P < .001). There were no significant changes in GH among times 1A, 2A, and 3A (P = .45) or times 1B and 2B (P = .12). Insulin concentrations increased after meals, but there were no changes from 4 am (8.5 ± 1.4 μU/mL) through 8 am (8.6 ± 1.1 μU/mL; P = .98). Glucose and insulin concentrations show no increase from 4-8 am; although there is variability in GH, there is no evidence for the dawn phenomenon in late pregnancy in healthy women.

Glucose Intolerance Mediated by Ghrelin through the Suppression of Insulin Secretion in Healthy Iraqi Children

Background:Ghrelin, identified as an endogenous ligand for the growth hormone secretagogue receptor, functions as a somatotrophic and orexigenic signal from the stomach. The secretion of ghrelin increases under conditions of negative energy balance, such as starvation, cachexia, and anorexia nervosa, whereas its expression decreases under conditions of positive energy-balance such as feeding, hyperglycemia, and obesity. In addition to having a powerful effect on the secretion of growth hormone, ghrelin stimulates food intake and transduces signals to hypothalamic regulatory nuclei that control energy homeostasis. Thus, it is interesting to note that the stomach may play an important role in not only digestion but also as a pituitary growth hormone release and central feeding regulation. Objective:The orexigenic gut hormone ghrelin and its receptor are present in pancreatic islets. Although ghrelin reduces insulin secretion in rodents, its effect on insulin secretion in humans has not been yet established. The goal of this study was to test the hypothesis that circulating ghrelin suppresses insulin secretion in healthy children. Subjects and methods : ELISA method was used to assay Ghrelin and Insulin . By taken blood sample from 40 obese children, 11 overweight children and 29 normal weight healthy children their age (5-11) years. Results: the mean of Ghrelin concentration was significantly lower in obese and overweight children than in controls ( P < 0.000 ) . The mean of Insulin concentration was significantly higher in obese and overweight children than in controls ( P < 0.007) . Negative correlation between Ghrelin and BMI also negative correlation between Ghrelin and Insulin. Conclusion: This study showed that ghrelin reduces insulin secretion and glucose disappearance in healthy children. This findings raise the possibility that endogenous ghrelin has a role in physiologic insulin secretion, and that it antagonists may improve β-cell function.

Mechanisms of actions of somatostatin on the regulation of pituitary growth hormone release in fish

Somatostatin is a multifunctional tetradecapeptide which is involved in growth,development, metabolism and reproductive processes,via the specific seven α helical transmembrane G-protein-coupled receptors( GPCRs). This review briefly summarizes the progress of research on somatostatin and its receptors,w ith special emphasis on the intracellular signaling mechanisms mediating somatostatin actions on the regulation of pituitary grow th hormone release in fish. To date,six somatostatin genes and four somatostatin receptors have been characterized in fish. The diversity of the somatostatin peptide family is due to the existence of multiple somatostatin genes as w ell as the tissue-specific differential processing of preprosomatostatin. The subtypes of somatostatin receptors are complex due to the polyploidization that occurred during fish lineage evolution. Information on the mechanisms of somatostatin suppression of GH secretion in teleosts is mainly derived from studies in goldfish,w hich indicates that cAMP formation,Ca2 + mobilization,and PKC activation may be involved in the mechanism through w hich somatostatin regulates GH secretion. How ever,the intricate w eb of intracellular signals is still far from being fully understood. In addition,species-specific differences in the mechanisms of GH release do exist in diverse models. The somatostatin genes,receptors and the mechanism of actions of somatostatin on pituitary GH release aw ait further studies in teleosts.

The Effect of Administration of Rutin on Plasma Levels of Estrogen, Prolactin, Growth Hormone and Gene Expression of Their Receptors in Mammary Glands in Ovariectomized Rats

The development of mammary glands, endocrine hormone concentrations and the gene expression of related receptors were measured in ovariectomized virgin rats after adminstration of an estrogen-like plant extract, rutin. Thirty-two ovariectomized virgin Wistar rats were randomly assigned to 4 treatments with 8 animals each: gastric infusion of 2 mL normal saline per unovariectomized rat per day (Sham), gastric infusion of 2 mL normal saline per ovariectomized rat per day (Ova), gastric infusion of 60 mg rutin kg−1 body weight (BW) per ovariectomized rat per day (Ova+Rut), or intramuscular injection of 60 μg estradiol kg−1 BW per ovariectomized rat weekly (Ova+Est). Samples of blood and mammary glands were harvested to determine the levels of estrogen (E2), prolactin (PRL) and growth hormone (GH), and the gene expression of estrogen receptors (ER), prolactin receptors (PRLR) and growth hormone receptors (GHR) with radioimmunoassy (RIA) and RT-PCR technology, respectively. The E2 concentration in plasma and gland tissues from the rats of Ovx+Rut or Ovx+Est was higher than that of Ovx (P<0.05), but the plasma E2 concentration from the rats of Ovx+Rut was lower than that of Sham (P<0.05). The order of the PRL concentration in plasma and gland tissues was Ovx<Ovx+Rut<Ovx+Est <Sham, and the difference in each treatment (P<0.05). The plasma GH concentration was lower in Ovx than in Ovx+Rut or Ovx+Est, and lower in Ovx+Rut than in Sham (P<0.05). The GH concentration in gland tissues was lower in Ovx than in Ovx+Rut or Ovx+Est (P<0.05), and lower in Ovx+Rut than in Sham (P<0.05). The gene expression of ER in gland tissues was increased in an order as Ovx<Ovx+Rut<Ovx+Est<Sham (P<0.05), and PRLR, GHR showed the same trend. In conclusion, adminstration of rutin increased the E2 concentration in plasma and mammary glands, promoted pituitary PRL and GH release, up-regulated the gene expression of ER, PRLR and GHR, and stimulated mammary development in ovariectomized virgin rats.